Marinus Pharma Q4 2023 GAAP EPS $(0.740) Misses $(0.630) Estimate, Sales $7.190M Miss $8.015M Estimate
Portfolio Pulse from Benzinga Newsdesk
Marinus Pharma (NASDAQ:MRNS) reported Q4 2023 GAAP EPS of $(0.740), missing the $(0.630) estimate, and sales of $7.190M, missing the $8.015M estimate. This represents a slight improvement over the previous year's losses and sales.
March 05, 2024 | 9:23 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Marinus Pharma reported a larger than expected quarterly loss and missed sales estimates for Q4 2023, indicating a slight improvement over the previous year.
Missing both EPS and sales estimates typically leads to negative investor sentiment in the short term. Although there's a slight improvement over the previous year, the miss on both fronts is likely to overshadow this and negatively impact MRNS's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100